We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




European Hospitals Invest in Advanced Wound Care Products

By HospiMedica International staff writers
Posted on 01 Jun 2014
The rising incidence of lifestyle diseases and an expanding, aging population are driving the sales volumes of wound care and closure products across Europe. More...
These are the latest findings of Frost & Sullivan (Frost; London, United Kingdom), an international market research firm.

Hospitals in both Western and Eastern Europe are increasingly showing a preference for advanced wound care products that accelerate healing, as they realize that prolonged hospital stays and bed occupancy are a bigger cost burden than investment in these solutions. Patients as well are finding that advanced wound care products are easier to use and more comfortable than traditional ones, giving a boost to the adoption rates. The increase in the volume of open surgical procedures is also fuelling demand for wound closure products.

As a result, doctors across Western and Eastern Europe are particularly adopting new wound closure technologies that support scar-free surgery. However, the lack of reimbursement for some of these advanced wound care and closure products is lowering market potential. The market is further complicated by the proliferation of products from Asian markets and other regions. Moreover, the inability of hospitals to invest in costly technologies such as negative pressure wound therapy (NPWT) is forcing market participants to reassess their pricing strategies.

“Wound care product manufacturers have already started making NPWT and other active therapies more affordable by introducing rental models, portable solutions, and other cost-effective alternatives,” said Frost & Sullivan healthcare research analyst Parthasarathy Raghava. “They should continue finding ways to ensure that high-technology wound care solutions fit into current healthcare budgets.”

According to the Frost report, innovative pricing strategies and product differentiation will be vital to increase profits, and wound closure product manufacturers will do well to launch products that have unique features and can deal with multiple types of wounds to stand out from the competition. Frost & Sullivan have found that the Western and Eastern European wound care and wound closure market earned revenues of USD 4.41 billion in 2013, and estimates that this could reach USD 6.41 billion in 2019.

Related Links:

Frost & Sullivan




Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.